Navigation Links
Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
Date:4/4/2011

NEW ORLEANS and CHAPEL HILL, N.C., April 4, 2011 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's (ACC) 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Preclinical results highlighted in the first abstract demonstrate CXL-1020's ability to work independently from other heart failure therapies, furthering important insights into the cellular mechanism of action of nitroxyl donors. Clinical results presented in the second abstract demonstrate, for the first time, CXL-1020's safety and tolerability in people who have stable congestive heart failure (CHF), a good predictor of safety in people with acute decompensated heart failure (ADHF).  

"Today's research findings provide additional support for the unique mechanism of CXL-1020 and for its strong safety profile and tolerability in patients with stable CHF," said Chris Kroeger, M.D., President and Chief Executive Officer.  "We are currently enrolling a Phase IIa clinical trial to further define safety, tolerability and dosing for CXL-1020 in patients with ADHF, bringing us closer to making this treatment a reality for the millions who suffer from this disease."  

Following are the details of the data presented at ACC Poster Sessions:

CXL-1020, a Novel HNO Donor, Decreases Myocardial Loading and Enhances Load-Independent Lusitropy and Inotropy via a Beta-AR/ACE Independent Mechanism. Monday, April 4, 2011; 1:45 p.m. – 4:45 p.m., Ernest N. Morial Convention Center, Hall F; Poster Board #21

In this preclinical study, Cardioxyl and QTest Labs researchers compared the hemodynamic profile of CXL-1020 with the vasodilator, sodium nitroprusside (SNP).  The results show that under conditions of matched reduction of systolic pressure, CXL-1020 and SNP increased stroke volume without incre
'/>"/>

SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... WORCESTER, Mass. and ... -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB: ... intention to implement a buccal cannabis co-development ... ) has been formalized. Generex ... Co-Development and Technology Licensing Agreement.  Pursuant to ...
(Date:9/2/2015)... ROCKVILLE, Md. , Sept. 2, 2015 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... J.J. Finkelstein , President and Chief Executive ... Rodman & Renshaw Global Investment Conference, sponsored by ... will be held September 8-10, 2015 at the ...
(Date:9/2/2015)... DIEGO , Sept. 2, 2015  MEI Pharma, ... on the clinical development of novel therapies for cancer, ... 30, 2015. Logo - http://photos.prnewswire.com/prnh/20140805/133834 ... fiscal year, I am quite pleased with how the ... Daniel P. Gold , Ph.D., President and Chief Executive ...
Breaking Medicine Technology:Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7
... CLINTON, N.J., Jan. 5, 2011 Ikaria, Inc. today ... has granted INOMAX® (nitric oxide) for inhalation an additional ...  The action extends exclusivity for INOMAX from January 2013 ... submitted from three clinical trials of INOMAX in pre-term ...
... Jan. 5, 2011 Consumer Electronics Show Las Vegas ... Hamilton CapTel ® will demonstrate the CapTel 800i® captioned ... Electronics Show (CES) in Las Vegas January 6 – ... Ears debut their marketing partnership while exhibiting together at ...
Cached Medicine Technology:FDA Extends Marketing Exclusivity for INOMAX® 2FDA Extends Marketing Exclusivity for INOMAX® 3Hamilton CapTel® and Partner TV Ears to Display Telephone Communication Technology Designed for Individuals with Hearing Loss at Consumer Electronics Show 2Hamilton CapTel® and Partner TV Ears to Display Telephone Communication Technology Designed for Individuals with Hearing Loss at Consumer Electronics Show 3
(Date:9/2/2015)... KY (PRWEB) , ... September 02, 2015 , ... Ericson ... the CDI Education Director for HCPro and Associate Director of Education for the Association ... CDI, Advancing CDI and ICD-10 for CDI Boot Camps. She serves as a CDI ...
(Date:9/2/2015)... ... September 02, 2015 , ... The 2015 China Overseas ... investment and business conference will be hosted at five star Beijing Kunlun Hotel ... networking conference will feature leading EB-5 industry professionals and Chinese private equity partners ...
(Date:9/2/2015)... Minneapolis, MN (PRWEB) , ... September 02, 2015 ... ... is commercializing products for the upper extremity surgical market, announced today that more ... instrument for trigger releases in the hand. Plus, nearly 70 of these ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... On September ... to attend doTERRA’s annual convention, the largest single-company convention to date for the state ... and look forward to a tremendous event,” states David Stirling, doTERRA CEO. “One of ...
(Date:9/2/2015)... ... September 02, 2015 , ... The payroll conference ... days of payroll education covering legislative updates, including unemployment, global payroll best practices, ... representatives from Ceridian, Ultimate Software, the American Payroll Association, Barnett Associates, and the ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... indeed a ‘ubiquitous’ festival, as it is celebrated throughout the ... 26 million Indian homes.// The joys of the season is ... making the most of the special bargains and discounts of ... the celebration. Plans are afoot in great enthusiasm as homes ...
... The surprising structure and properties of a protein responsible for ... it binds its target RNA// -- are described by researchers ... is an essential nutrient, and defects in uptake and metabolism ... a variety of diseases and disorders, including heart disease, arthritis ...
... Agricultural Research Service (ARS) funded research suggest that berry extracts ... found that laboratory animals, which were fed berry extracts and ... damage to brain function. ,Three groups ... for about three months. The control group was fed a ...
... Health plans, school girls as young as 12 could ... cause cervical cancer//. Researchers have found that the Human ... of cervical cancer, which kills around 1,000 women a ... the human papilloma virus (HPV) before they become sexually ...
... (AL) on Saturday voiced concern on the developments regarding the ... Libyan children with the HIV/AIDS virus//. AL also issued an ... ,The AL also expressed full sympathy underlining the ... order to curb the consequences of this "painful human catastrophe". ...
... (FDA) is expected to announce soon the results of its ... some species of cloned animals. ,Two experts ... Agriculture Policy are available to media to comment on the ... safety of consuming meat and milk from cloned animals. ...
Cached Medicine News:Health News:Come Apart and Rest Awhile – It’s Christma 2Health News:Come Apart and Rest Awhile – It’s Christma 3Health News:Structure of Iron Regulatory Protein-RNA Complex Solved 2
... Vascular Graft, the newest vascular graft offering ... leader in vascular surgical products for more ... reducing kinking and compression problems that ... graft provides all of the benefits of ...
... rasping necessary in cruciate ligament reconstruction procedures ... bone surface. This condition, if not rectified ... cruciate replacement. The GORE SMOOTHER Crucial Tool ... procedures. The tool functions as both a ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... system has been designed by practicing ... of the ever changing and demanding ... analyzing data from multiple modalities, including: ... and multiple patients at multiple sites. ...
Medicine Products: